+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adrenocorticotropic Hormone Receptor "

Adrenocorticotropic Hormone Receptor Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Adrenocorticotropic Hormone Receptor Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • May 2023
  • 79 Pages
  • Global
From
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 51 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The Adrenocorticotropic Hormone Receptor (ACTHR) is a G-protein coupled receptor (GPCR) that is involved in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis. It is a key target for the treatment of endocrine and metabolic disorders, such as Cushing's syndrome, Addison's disease, and adrenal insufficiency. ACTHR agonists and antagonists are used to modulate the activity of the HPA axis, and can be used to treat a variety of endocrine and metabolic disorders. Several pharmaceutical companies are involved in the development of ACTHR-targeted drugs. These include AbbVie, AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more